<unk>  is a combination of a nucleoside metabolic inhibitor and a thymidine phosphorylase inhibitor that is FDA approved for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.   Common adverse reactions include fatigue, nausea, diarrhea, decreased appetite, abdominal pain, anemia, neutropenia, thrombocytopenia, weakness, and fever.
Trifluridine and tipiracil
Foscarnet sodium
Ado-trastuzumab emtansine
Tegafur-uracil
Daunorubicin / cytarabine
Azacytidine
Temsirolimus
Decitabine